Javascript must be enabled to continue!
Anti –NMDA receptor encephalitis in children: A study from Eastern India
View through CrossRef
Introduction: Anti-N-methyl-d-aspartate receptor (Anti-NMDAr) encephalitis is the second common cause of autoimmune encephalitis.Objectives: To describe the clinico-epidemiological profile, treatment, and outcome of paediatric anti-NMDAr encephalitis patients.Method: This is a retrospective, observational study in a tertiary care hospital from eastern India with 16 anti-NMDAr encephalitis cases aged <12 years. All patients were positive for cerebrospinal fluid (CSF) anti NMDAr antibody. Graus criteria were used for case detection and modified Rankin scale for assessing neurological disability before and after treatment. All cases received first line immunotherapy with intravenous immunoglobulin (IVIG), methyl prednisolone or both; those with failure to respond or worsening were considered for second line immunotherapy.Results: The 16 patients were aged 6 months to 11 years (mean 7.7 years); 43.8% were female; they were diagnosed by an average 25 days; speech defects (93.8%), psychiatric manifestations (100%) and seizures (87.5%) were the early features. CSF anti NMDAr antibody was positive in 100% and electro-encephalographic (EEG) changes were found in 100%. There were no tumours in pelvis or abdomen on ultrasonography. Magnetic resonance imaging abnormalities were present in 62.5%. First line immunotherapy consisting of only IVIG (18.8%), only methyl prednisolone (6.25%) and both IVIG and methyl prednisolone (75%) was started by a median 30 days, with better response in the latter group. Seven (43.8%) patients received second line immunotherapy (Rituximab) with prompt response Twelve (75%) cases are under regular follow up. Oral prednisolone was continued for one year in the initial 8 cases. In the remaining 4 cases, steroids were tapered when serum anti NMDAr antibody became negative. Relapse was noted in one case.Conclusions: Speech defects (93.8%), psychiatric manifestations (100%) and seizures (87.5%) were early features. Positive CSF anti NMDAr antibody and EEG changes were found in 100%. First line immunotherapy consisted of IVIG and methyl prednisolone.Sri Lanka Journal of Child Health, 2022; 51(4): 513-518
Sri Lanka Journals Online
Title: Anti –NMDA receptor encephalitis in children: A study from Eastern India
Description:
Introduction: Anti-N-methyl-d-aspartate receptor (Anti-NMDAr) encephalitis is the second common cause of autoimmune encephalitis.
Objectives: To describe the clinico-epidemiological profile, treatment, and outcome of paediatric anti-NMDAr encephalitis patients.
Method: This is a retrospective, observational study in a tertiary care hospital from eastern India with 16 anti-NMDAr encephalitis cases aged <12 years.
All patients were positive for cerebrospinal fluid (CSF) anti NMDAr antibody.
Graus criteria were used for case detection and modified Rankin scale for assessing neurological disability before and after treatment.
All cases received first line immunotherapy with intravenous immunoglobulin (IVIG), methyl prednisolone or both; those with failure to respond or worsening were considered for second line immunotherapy.
Results: The 16 patients were aged 6 months to 11 years (mean 7.
7 years); 43.
8% were female; they were diagnosed by an average 25 days; speech defects (93.
8%), psychiatric manifestations (100%) and seizures (87.
5%) were the early features.
CSF anti NMDAr antibody was positive in 100% and electro-encephalographic (EEG) changes were found in 100%.
There were no tumours in pelvis or abdomen on ultrasonography.
Magnetic resonance imaging abnormalities were present in 62.
5%.
First line immunotherapy consisting of only IVIG (18.
8%), only methyl prednisolone (6.
25%) and both IVIG and methyl prednisolone (75%) was started by a median 30 days, with better response in the latter group.
Seven (43.
8%) patients received second line immunotherapy (Rituximab) with prompt response Twelve (75%) cases are under regular follow up.
Oral prednisolone was continued for one year in the initial 8 cases.
In the remaining 4 cases, steroids were tapered when serum anti NMDAr antibody became negative.
Relapse was noted in one case.
Conclusions: Speech defects (93.
8%), psychiatric manifestations (100%) and seizures (87.
5%) were early features.
Positive CSF anti NMDAr antibody and EEG changes were found in 100%.
First line immunotherapy consisted of IVIG and methyl prednisolone.
Sri Lanka Journal of Child Health, 2022; 51(4): 513-518.
Related Results
Anesthesia for patient with anti-N-methyl-D-aspartate receptor encephalitis
Anesthesia for patient with anti-N-methyl-D-aspartate receptor encephalitis
AbstractRationale:Anti-N-methyl-D-aspartate (NMDA) receptor encephalitis is an immune-mediated syndrome caused by the production of antibodies against NMDA receptors. As NMDA recep...
Encephalitis lethargica: clinical features and aetiology
Encephalitis lethargica: clinical features and aetiology
Abstract
Encephalitis lethargica, an epidemic neurological illness, typically involved a severe sleep disorder and progressive parkinsonism. A century later, our und...
Anti-NMDA Receptor Encephalitis: A Narrative Review
Anti-NMDA Receptor Encephalitis: A Narrative Review
Antibodies against the NR1 or NR2 subunits of the NMDA receptor are linked to anti-N-methyl-D-aspartate (NMDA) receptor encephalitis, a type of encephalitis that mainly affects wom...
Trends in Encephalitis-Associated Deaths in the United States, 1999-2008
Trends in Encephalitis-Associated Deaths in the United States, 1999-2008
<b><i>Background:</i></b> While encephalitis may be caused by numerous infectious, immune and toxic processes, the etiology often remains unknown. <b>...
High sensitivity and specificity in proposed clinical diagnostic criteria for anti‐N‐methyl‐D‐aspartate receptor encephalitis
High sensitivity and specificity in proposed clinical diagnostic criteria for anti‐N‐methyl‐D‐aspartate receptor encephalitis
AimTo determine the validity of the proposed clinical diagnostic criteria for anti‐N‐methyl‐d‐aspartate receptor (NMDAR) encephalitis in paediatric patients.MethodThe diagnostic cr...
Experience with anti NMDA receptor antibody encephalitis in a tertiary care hospital in Pakistan
Experience with anti NMDA receptor antibody encephalitis in a tertiary care hospital in Pakistan
Background and objective:
Anti NMDA receptor (Anti-NMDAR) antibody encephalitis is an increasingly recognized form of auto immune encephalitis. The objective of this study w...
Changes in NMDA Receptor Function in Rapid Ischemic Tolerance: A Potential Role for Tri-Heteromeric NMDA Receptors
Changes in NMDA Receptor Function in Rapid Ischemic Tolerance: A Potential Role for Tri-Heteromeric NMDA Receptors
In this study, we characterize biophysical changes in NMDA receptor function in response to brief non-injurious ischemic stress (ischemic preconditioning). Electrophysiological stu...
Quantitative EEG as a Prognostic Tool in Suspected Anti-N-Methyl-d-Aspartate Receptor Antibody Encephalitis
Quantitative EEG as a Prognostic Tool in Suspected Anti-N-Methyl-d-Aspartate Receptor Antibody Encephalitis
Purpose:
Anti–N-methyl-d-aspartate receptor (anti-NMDAR) encephalitis is a form of autoimmune encephalitis associated with EEG abnormalities. In view of the potentially...

